ArticleThe Journal of clinical endocrinology and metabolism2025
Metabolic Dysfunction-associated Steatotic Liver Disease Alters Fatty Acid Profiles in the Liver and Adipose Tissue.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- NMR metabolomic signatures of healthy lifestyle and incident MASLD.Scientific reports · 2026Article
- TSP50 attenuates metabolic dysfunction-associated steatotic liver disease via SCD1 degradation-mediated suppression of hepatocyte lipogenesis.Cellular & molecular biology letters · 2026Article
- Ferroptosis in metabolic dysfunction-associated steatotic liver disease.Frontiers in immunology · 2026Review
- Metabolic Dysfunction-associated Steatotic Liver Disease Alters Fatty Acid Profiles in the Liver and Adipose Tissue.The Journal of clinical endocrinology and metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
contextThe alterations in systemic fatty acid (FA) metabolism in metabolic dysfunction-associated steatotic liver disease (MASLD) remain unclear.
objectiveTo investigate intertissue crosstalk in FA metabolism in patients with MASLD, we compared FA profiles in the liver, serum, visceral, and subcutaneous adipose tissue of patients with severe obesity and normal liver, simple steatosis, or metabolic dysfunction-associated steatohepatitis (MASH).
methodsPreoperative serum, liver, subcutaneous, and visceral adipose tissue samples were collected during laparoscopic gastric bypass surgery from 183 patients with severe obesity (122 women, mean age 46.9 ± 9.7 years, body mass index 43.5 ± 5.7 kg/m2). FA composition was analyzed using gas-liquid chromatography. The Kruskal-Wallis test was used to compare the FA proportions in different tissue depots.
resultsFA proportions varied more in the liver than in adipose tissue in patients with MASH. Polyunsaturated FAs (PUFA) proportions were significantly lower in the livers of patients with MASH than in those with normal livers (all adjusted P < .01). Conversely, dihomo-gamma-linolenic acid, adrenic acid, and arachidonic acid proportions were higher in the adipose tissues of patients with MASH (all adjusted P < .001).
conclusionPatients with MASH exhibited reduced hepatic PUFA content, increased hepatic saturated FAs, and a higher n6-to-n3 PUFA ratio, whereas no clear trends were observed in adipose tissue. These findings highlight distinct differences in FA metabolism between the liver and adipose tissue in MASLD, emphasizing tissue-specific regulatory mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.